#279 - AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins
whatshot 29 snips
Nov 13, 2023
In this engaging discussion, various pharmacological tools for boosting metabolic health are explored, including SGLT-2 inhibitors, metformin, and GLP-1 agonists. The potential of SGLT-2 inhibitors as geroprotective agents is closely examined, shedding light on their effects beyond managing blood sugar levels. Additionally, the relationship between statins and insulin resistance is unpacked, discussing the implications for type 2 diabetes risk and overall metabolic health. Strategies for monitoring statin effects and risk reduction are also highlighted.
27:10
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
SGLT2 Inhibitor Mechanism
SGLT2 inhibitors lower blood glucose by blocking glucose reabsorption in the kidneys.
This differs from other diabetes medications that increase insulin sensitivity or production.
question_answer ANECDOTE
Phlorizin and SGLT2 Inhibitors
SGLT2 inhibitors were developed from phlorizin, a natural substance found in apples.
Phlorizin causes glucosuria (glucose in urine), which led to its use in early diabetes diagnosis.
insights INSIGHT
SGLT2 Inhibitor Variations
There are four FDA-approved SGLT2 inhibitors with similar structures but different potencies and dosages.
They share a glucose ring with an aromatic group, differentiating them from phlorizin's basic structure.
Get the Snipd Podcast app to discover more snips from this episode
In this “Ask Me Anything” (AMA) episode, Peter explores various pharmacologic tools commonly utilized to improve metabolic health and treat diabetes, including SGLT-2 inhibitors, metformin, and GLP-1 agonists. He examines the available data on these drugs, assessing their comparative effectiveness and their potential in the context of lifestyle interventions. Additionally, he offers insights into whether SGLT2 inhibitors hold promise as geroprotective agents beyond their effects on glycemic control. Next, Peter analyzes the relationship between statin usage and the risk of developing insulin resistance and type 2 diabetes, investigating possible causal pathways and providing insights into strategies for risk reduction. He offers insights on monitoring adverse statin effects and evaluating the need for adjustments, ultimately weighing the trade-off between the risk to overall metabolic health against the benefits of reducing apoB levels through statin use.
If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #53 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
Pharmacologic tools for improving metabolic health, and the relationship between statins and insulin resistance [2:00];
SGLT-2 inhibitors: how they work and help to manage type 2 diabetes [4:15];
The history of SGLT2 inhibitors – from discovery to the current state [10:15];
Comparing the various FDA-approved SGLT2 inhibitors [15:00];
Other beneficial effects of SGLT2 inhibitors outside of glycemic control [20:15];
Exploring SGLT2 inhibitors as potential geroprotective molecules [22:45];
The side effects and risks associated with SGLT2 inhibitors [31:45];
Medications, lifestyle interventions, and other considerations for treating diabetes and improving metabolic health [37:45];
Metformin as a tool for pre-diabetics, and how metformin compares to lifestyle interventions [44:00];
How GLP-1 agonists compare to metformin and SGLT2 inhibitors in terms of glycemic control and weight loss [49:15];
Exploring the relationship between statin use and the risk of developing insulin resistance and type 2 diabetes [52:30];
Possible mechanisms of statin-induced insulin resistance and diabetes, and potential mitigation strategies [1:04:30];
How to monitor for adverse effects of statin use and assess the need for adjustments [1:11:45];
Weighing the benefits and risks of statin use: does the diabetes risk outweigh the benefits of lowering apoB with a statin? [1:15:30];
The Peter Attia Drive